CX717

CX717
Clinical data
Routes of
administration		By mouth, IV
ATC code
  • None
Identifiers
  • 5-(Morpholine-4-carbonyl)-2,1,3-benzoxadiazole[1][2]
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC11H11N3O3
Molar mass233.227 g·mol−1
3D model (JSmol)
  • C1COCCN1C(=O)C2=CC3=NON=C3C=C2
  • InChI=1S/C11H11N3O3/c15-11(14-3-5-16-6-4-14)8-1-2-9-10(7-8)13-17-12-9/h1-2,7H,3-6H2
  • Key:KFRQROSRKSVROW-UHFFFAOYSA-N
 ☒NcheckY (what is this?)

CX717 is an ampakine compound created by Christopher Marrs and Gary Rogers in 1996[3] at Cortex Pharmaceuticals. It affects the neurotransmitter glutamate, with trials showing the drug improves cognitive functioning and memory.[4]

  1. ^ Radin DP, Purcell R, Lippa AS (January 2018). "Oncolytic Properties of Ampakines In Vitro". Anticancer Research. 38 (1): 265–269. doi:10.21873/anticanres.12217. PMID 29277782.
  2. ^ Purcell R, Lynch G, Gall C, Johnson S, Sheng Z, Stephen MR, et al. (April 2018). "Brain Vacuolation Resulting From Administration of the Type II Ampakine CX717 Is An Artifact Related to Molecular Structure and Chemical Reaction With Tissue Fixative Agents". Toxicological Sciences. 162 (2): 383–395. doi:10.1093/toxsci/kfx277. PMID 29253237.
  3. ^ US 6110935, Rogers GA, Marrs CM, "Benzofurazan compounds for enhancing glutamatergic synaptic responses", issued 29 August 2000, assigned to University of California. 
  4. ^ Hampson RE, España RA, Rogers GA, Porrino LJ, Deadwyler SA (January 2009). "Mechanisms underlying cognitive enhancement and reversal of cognitive deficits in nonhuman primates by the ampakine CX717". Psychopharmacology. 202 (1–3): 355–369. doi:10.1007/s00213-008-1360-z. PMC 3107999. PMID 18985324.